Welcome to our dedicated page for Apyx Medical news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical stock.
Apyx Medical Corporation reports news on its surgical aesthetics medical-device business, including products marketed as Renuvion, the AYON Body Contouring System, and J-Plasma. Updates commonly cover FDA 510(k) clearances, body contouring capabilities, controlled-heat tissue applications, commercial activity in cosmetic surgery and hospital surgical markets, and OEM agreements with other medical device manufacturers.
The company’s recurring financial releases discuss revenue by its Surgical Aesthetics and Original Equipment Manufacturing segments, product demand for generators and single-use handpieces, U.S. and international sales trends, and management conference participation.
Apyx Medical Corporation (NASDAQ:APYX) has submitted a 510(k) premarket notification to the FDA seeking a specific clinical indication for its Renuvion device in dermal resurfacing procedures. This submission follows the recent completion of a U.S. IDE clinical study and signifies a crucial milestone for the company in expanding its market potential. CEO Charlie Goodwin noted the team's efforts in achieving this progress and expressed optimism regarding the FDA's review process.
Apyx Medical Corporation (NASDAQ:APYX) reported a significant increase in total revenue for Q1 2021, reaching $8.6 million, a 72.9% rise YoY. Advanced Energy revenue surged 92.2% to $7.7 million, while OEM revenue dipped 3.3% to $1.0 million. The company posted a net loss of $4.9 million, greater than the $2.0 million loss from Q1 2020. Cash reserves stood at $39.5 million. Full-year guidance was raised, projecting total revenue between $37.6 million and $39.7 million, a 36% to 43% growth from 2020.
Apyx Medical Corporation (NASDAQ:APYX) will release its financial results for Q1 2021 on May 12 before the market opens. A conference call is scheduled for 8:00 a.m. ET on the same day, where management will discuss the quarter's results and address questions. Interested listeners can join via phone or access the live webcast on the Company’s website. A telephonic replay of the call will be available shortly after, until May 21. Apyx Medical Corporation is known for its innovative Helium Plasma Technology, marketed as Renuvion® and J-Plasma®, in cosmetic and surgical markets.
Apyx Medical Corporation (NASDAQ:APYX) reported a strong fourth quarter for 2020 with total revenue of $11.5 million, up 36.8% year-over-year. Advanced Energy revenue increased 44.0% to $9.9 million. The net loss narrowed to $1.5 million from $5.4 million a year earlier. However, full-year revenue fell 1.9% to $27.7 million. The company forecasts 2021 revenue of $36.7 million to $38.7 million, projecting 32% to 40% growth, led by Advanced Energy growth of 45% to 55%.
Apyx Medical Corporation (NASDAQ:APYX) will release its financial results for Q4 and fiscal year 2020 on March 31, 2021, before the market opens. A conference call is scheduled for 8:00 a.m. ET on the same day, allowing stakeholders to discuss the results and engage in a Q&A session. The call can be accessed by phone or through a live webcast on the Company’s website. Apyx Medical specializes in advanced energy technologies, notably its Helium Plasma Technology marketed as Renuvion® and J-Plasma®, aimed at improving precision in cosmetic and surgical procedures.
Apyx Medical Corporation (NASDAQ:APYX) announced preliminary revenue results for Q4 and full year 2020, with Q4 revenue between $10.9 to $11.3 million, marking a 30% to 35% year-over-year increase. Advanced Energy revenue in Q4 is estimated at $9.5 to $9.8 million, a 39% to 43% growth. However, total annual revenue is expected to be $27.1 to $27.5 million, reflecting a 3% to 4% decline. CEO Charlie Goodwin highlighted strong performance despite COVID-19 challenges, with expectations for continued improvement and a $1.5 billion addressable market in the U.S.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in the virtual ICR Conference 2021, scheduled for January 11th-14th. Management will host a fireside chat on January 14th at 9:15 a.m. Eastern Time. A live audio webcast will be accessible on the Apyx investor relations website, with an archived replay available post-conference.
Apyx is known for its innovative Helium Plasma Technology, marketed as Renuvion® and J-Plasma®, aimed at enhancing precision in cosmetic and surgical procedures.
Apyx Medical Corporation (NASDAQ:APYX) announced FDA approval to commence Phase II of its IDE clinical study for Renuvion® technology, aimed at skin laxity procedures in the neck and submental region. The approval includes updates to the treatment protocol, a revised statistical analysis plan, and an increase in investigational sites. Enrollment of 65 study subjects is expected to start in early December, with completion targeted for the third quarter of 2021. The company emphasizes its innovative Helium Plasma Technology in both cosmetic and surgical markets.
Apyx Medical Corporation (NASDAQ:APYX) reported a total revenue of $7.0 million for Q3 2020, reflecting an 8.2% decline year-over-year. Advanced Energy revenue fell 10.1% to $5.5 million, while OEM revenue slightly decreased 0.4% to $1.5 million. The GAAP net loss improved to $3.7 million from $4.4 million in Q3 2019. Cash and cash equivalents stood at $43.5 million at quarter-end. The company anticipates a cautious recovery in demand linked to the ongoing impacts of the COVID-19 pandemic.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in several upcoming investor conferences. The schedule includes a presentation at the Stifel 2020 Virtual Healthcare Conference on November 16 at 4:40 p.m. ET, and virtual 1x1 meetings at both the 11th Annual Craig-Hallum Alpha Select Conference on November 17 and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19. Additionally, a fireside chat will take place at the 32nd Annual Piper Sandler Healthcare Conference from December 1 to 3. Webcasts of these events will be accessible on the Apyx investor relations website.